Table 2.

Characteristics and treatment of patients with acute graft-versus-host disease (aGvHD).

pa	GvHD (global grade)	Organ	Treatment	Infections before GvHD treatment	T cell chimerism (%)b	Outcome
1	II	Skin, intestine	PDN, Leukotac	Staphylococcus epidermidis	NR	100
2	II	Skin, intestine	PDN, Leukotac	Noc	PR	70
3	III	Liver, intestine	PDN, MMF, Leukotac, ATG	Candida albicans, Streptococcus viridans	NR	100
4	II	Skin	PDN	No	CR	100
5	II	Skin, liver	PDN	Staphylococcus epidermidis	CR	100
6	I	Skin	PDN	Enterococcus faecium	CR	100
7	I	Skin	CsA, PDN, MMF	No	CR	100
8	II	Skin, liver	PDN, Leukotac, ATG	Staphylococcus aureus	NR	100
9	II	Skin, intestine	PDN	No	CR	100

ATG: anti-thymocyte immunoglobulin; CR: complete response; CsA: cyclosporin A; MMF: micophenolate mophetil; NR: non-response; PDN: prednisone; PR: partial response

^apatient number

^bchimerism at the time of aGvHD

^cwithout infections.